Okderma - Company finances
|
EUR
|
2022
From: 2022-07-25
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|
|
Financial data
|
||||
| Sales revenue | 5,860 | 32,525 | 66,759 | 55,938 |
| Profit before tax | 2,644 | 3,550 | 3,081 | 2,112 |
| Net profit | 2,512 | 3,354 | 2,927 | 1,985 |
| Equity | 2,561 | 5,916 | 6,843 | 6,228 |
| Liabilities | 1,132 | 1,207 | 712 | 6,144 |
| Non-current assets | 2,350 | 1,750 | 2,220 | 1,264 |
| Current assets | 1,343 | 4,829 | 5,335 | 11,108 |
| Total assets | 3,693 | 6,579 | 7,555 | 12,372 |
|
Taxes paid
|
||||
| STI taxes | - | 269 | 882 | 6,859 |
|
Financial indicators
|
||||
| Revenue change y/y | - | +455.0% | +105.3% | -16.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 68.0% | 51.0% | 38.7% | 16.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 98.1% | 56.7% | 42.8% | 31.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 42.9% | 10.3% | 4.4% | 3.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 45.1% | 10.9% | 4.6% | 3.8% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.4 | 0.2 | 0.1 | 1.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 32,525 | 66,759 | 55,938 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Okderma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-08-26 | 2026-09-02 | 0.12 |
| 2026-08-23 | 2026-08-23 | 0.12 |
| 2026-08-19 | 2026-08-19 | 0.12 |
| 2026-07-19 | 2026-08-02 | 0.12 |
| 2026-07-16 | 2026-07-17 | 0.12 |
| 2026-06-16 | 2026-07-02 | 0.12 |
| 2026-06-11 | 2026-06-14 | 0.12 |
| 2026-05-17 | 2026-06-08 | 0.12 |
| 2026-05-03 | 2026-05-14 | 0.12 |
| 2026-04-20 | 2026-04-29 | 0.12 |
| 2026-03-29 | 2026-04-15 | 0.12 |
| 2026-03-15 | 2026-03-27 | 0.12 |
| 2026-01-21 | 2026-03-11 | 0.12 |
| 2025-10-16 | 2025-10-19 | 91.61 |
| 2024-04-23 | 2024-05-12 | 0.58 |
| 2024-01-16 | 2024-01-17 | 203.87 |
Okderma - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company Okderma is: 0 €
| From | To | Overdue, € |
|---|---|---|
| 2026-09-01 | 2026-09-02 | 0.33 |
| 2026-08-28 | 2026-08-31 | 0.16 |
| 2026-07-30 | 2026-08-26 | 0.16 |
| 2026-07-01 | 2026-07-07 | 0.16 |
| 2026-04-30 | 2026-05-25 | 0.06 |
| 2026-03-29 | 2026-04-23 | 0.06 |
| 2026-02-28 | 2026-03-28 | 0.06 |
| 2026-02-21 | 2026-02-21 | 97.0 |
| 2026-02-16 | 2026-02-20 | 199.82 |
| 2025-10-02 | 2025-10-18 | 24.06 |
| 2025-09-30 | 2025-10-01 | 23.76 |
| 2025-09-28 | 2025-09-29 | 23.7 |
| 2025-08-28 | 2025-09-25 | 1.7 |
| 2025-07-31 | 2025-08-25 | 1.7 |
| 2025-07-28 | 2025-07-30 | 1.71 |
| 2025-06-30 | 2025-07-25 | 1.71 |
| 2025-06-28 | 2025-06-29 | 1.75 |
| 2025-06-19 | 2025-06-25 | 1.75 |
| 2025-04-30 | 2025-05-24 | 1.57 |
| 2025-04-28 | 2025-04-29 | 1.58 |
| 2025-04-27 | 2025-04-27 | 0.38 |
| 2025-04-02 | 2025-04-26 | 1.58 |
| 2025-03-28 | 2025-04-01 | 1.4 |
| 2025-03-27 | 2025-03-27 | 0.2 |
| 2025-03-02 | 2025-03-26 | 1.4 |
| 2025-02-28 | 2025-03-01 | 1.2 |
| 2025-01-31 | 2025-02-26 | 1.2 |
| 2025-01-30 | 2025-01-30 | 1.33 |
| 2025-01-01 | 2025-01-25 | 1.33 |
| 2024-12-29 | 2024-12-31 | 1.32 |
| 2024-12-22 | 2024-12-28 | 1.27 |
| 2024-12-21 | 2024-12-21 | 5.59 |
| 2024-12-20 | 2024-12-20 | 192.8 |
| 2024-12-03 | 2024-12-19 | 191.83 |
| 2024-11-28 | 2024-12-02 | 207.95 |
| 2024-11-26 | 2024-11-27 | 4.02 |
| 2024-11-17 | 2024-11-23 | 6.59 |
| 2024-10-13 | 2024-10-16 | 196.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Okderma, MB (code 306120760) is a Small partnership engaged in beauty care and other beauty treatment activities. In the latest financial year, 2025, the company generated revenue of €55.9K and net profit of €2.0K, corresponding to a profit margin of 3.5%. Revenue declined by 16.2% year on year from €66.8K in 2024, but remained well above the €32.5K reported in 2023, so the 2-year revenue change was +72.0%. Profitability weakened over the period: net profit fell from €3.4K in 2023 to €2.9K in 2024 and €2.0K in 2025. At year-end 2025, total assets stood at €12.4K, equity at €6.2K and liabilities at €6.1K, with a balance sheet that expanded mainly through short-term assets of €11.1K. Key ratios for 2025 include ROE of 31.9%, ROA of 16.0%, debt-to-equity of 0.99 and asset turnover of 4.52x. Revenue per employee was €55.9K and profit per employee €2.0K.